Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation safety study of psilocybin extract in healthy adults
RBR-2phymmgPhase 1Not yet recruiting
- Sponsor
- Instituto Alma Viva
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin, sponsored by Instituto Alma Viva. Primary endpoints: Tolerability and Safety. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
psilocybin
Beyond the preview
Go deeper on RBR-2phymmg.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2phymmg.